Navigation Links
Halozyme to Host First Quarter 2012 Financial Results Conference Call
Date:4/30/2012

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
2. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
3. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
4. Halozyme Announces Proposed Public Offering of Common Stock
5. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
6. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
7. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
8. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
9. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
10. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
11. Halozyme Therapeutics to Present at Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Dutch surgeons have launched a ... the world and treat patients on a global scale. Medical professionals ... Asia and the US have already signed ... and networking in a totally secure environment. Education  ... zone working together with a surgeon at Harvard to treat a ...
(Date:5/23/2016)... , May 23, 2016 Global ... 163 pages, profiles 12 companies and the Paclitaxel analysis ... figures on the industry and its players. ... comprehensive in nature, details the current state of the ... including definitions, classifications, applications and industry chain structure. The ...
(Date:5/23/2016)... , May 23, 2016 ... Size, Share, Development, Growth and Demand Forecast to ... and Other), by Application (Drug Discovery and Development, ... Users (Pharmaceuticals, Life Science and Biotechnology, Academic and ... Market Research, the global mass spectrometry market ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a small town with ... citizens formed an organization, Madeira Beach United, to oppose two development projects undertaken by ... center to a high rise urban environment. , According to the Tampa Bay ...
(Date:5/26/2016)... ... ... According to the Webster’s dictionary, a hippie is defined as someone who ... is going against the norm with a line of all-natural skincare that’s effective, afforable ... space is proud to announce its latest retail partnership with the Vitamin Shoppe. Launching ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... weekend to host their second pop-up shop for three consecutive weekends. The pop-up ... to the Santa Barbara community, a community full of women who appreciate the ...
(Date:5/26/2016)... Malvern, PA (PRWEB) , ... May 26, 2016 ... ... Sharon Wolf has been hired as FluidEdge’s Vice President of Business Intelligence and ... health analytics, Wolf has demonstrated success leading teams as a healthcare business and ...
(Date:5/25/2016)... ... 2016 , ... The United States Food and Drug Administration (FDA) has now ... women. To date, the company is the first and only manufacturer of low level ... with androgenetic alopecia. , “This new level of clearance substantiates what many physicians ...
Breaking Medicine News(10 mins):